Buscail E, Cauvin T, Fernandez B, Buscail C, Marty M, Lapuyade B, Subtil C, Adam JP, Vendrely V, Dabernat S, Laurent C, Chiche L.
Abstract
Background
The European Consensus 2018 established a new algorithm with absolute and relative criteria for intraductal papillary mucinous neoplasms of the pancreas (IPMN) management. The aim of this study was to validate these criteria and analyse the outcomes in function of the surgical procedure and IPMN subtype.
Methods
Clinical, radiological and surgical data (procedure, morbidity/mortality rates) of patients who underwent surgery for IPMN between 2007 and 2017. The predictive value of the different criteria was analysed.
RESULTs
124 patients (men 67%; mean age 65 years) underwent surgery for IPMN (n = 62 malignant tumours; 50%). Jaundice, cyst ≥4 cm and Wirsung duct size 5-9.9 mm or ≥ 10 mm were significantly associated with malignancy (4.77 < OR < 11.85 p < 0.0001). The positive predictive value of any isolated criterion ranged from 71 to 87%, whereas that of three relative criteria together reached 100%. The mortality and morbidity (grade III-IV complications according to the Dindo-Clavien classification) rates were 3 and 8%, respectively. Morbidity/mortality after duodenopancreatectomy and total pancreatectomy were significantly higher for benign IPMN (p = 0.01).
CONCLUSion
Considering the morbidity associated with extended surgery, particularly for benign IPMN, the results of the present study suggest that high-risk surgery should be considered only in the presence of three relative criteria and including the surgery type in the decision-making algorithm.
KEYWORDS
European guidelines; IPMN; Pancreatic resection; Post-operative morbidity.
Buscail E, Cauvin T, Fernandez B, Buscail C, Marty M, Lapuyade B, Subtil C, Adam JP, Vendrely V, Dabernat S, Laurent C, Chiche L. Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process. BMC Surg. 2019 Aug 22;19(1):115. doi: 10.1186/s12893-019-0580-y. PMID: 31438917; PMCID: PMC6704670.
